Xiamen Innovax Biotech Co., Ltd.
- Biotech or pharma, therapeutic R&D
- Other products or services
Founded in 2005, Innovax Biotech is committed to developing high-quality and affordable vaccines to combat infectious diseases worldwide, contributing China’s expertise to global public health. Leveraging its proprietary E. coli recombinant protein platform, a safer and more cost-effective technology compared to traditional yeast/baculovirus systems, the company has numerous vaccines currently in development and clinical trials. Its commercialized vaccines include Hecolin® (the world’s first HEV vaccine) , Cecolin® (China’s first bivalent HPV vaccine) and Cecolin®9 (China's first and the world's second 9-valent HPV vaccine). Cecolin® achieved WHO prequalification in 2021, securing market authorization in over 20 countries up to now and inclusion in national EPI of 7 countries. The recent approval of 9-valent HPV vaccine is a breakthrough which could help expand equitable access to HPV vaccination and contribute significantly to WHO's global cervical cancer elimination strategy.
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}